ResMed Inc. (ASX:RMD)
| Market Cap | 56.86B |
| Revenue (ttm) | 7.85B |
| Net Income (ttm) | 2.14B |
| Shares Out | n/a |
| EPS (ttm) | 14.51 |
| PE Ratio | 26.61 |
| Forward PE | 23.57 |
| Dividend | 0.50 (1.29%) |
| Ex-Dividend Date | Aug 13, 2025 |
| Volume | 1,214,698 |
| Average Volume | 1,073,606 |
| Open | 38.92 |
| Previous Close | 39.29 |
| Day's Range | 38.80 - 39.23 |
| 52-Week Range | 32.04 - 45.25 |
| Beta | 0.83 |
| RSI | 27.79 |
| Earnings Date | Oct 30, 2025 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial numbers in USD Financial StatementsNews
Morgan Stanley Updates Rating and Price Target for ResMed (RMD) | RMD Stock News
Morgan Stanley Updates Rating and Price Target for ResMed (RMD) | RMD Stock News
Zacks.com featured highlights include Stryker, NVIDIA, ResMed and Ralph Lauren
Zacks highlights four GARP (Growth at a Reasonable Price) stocks Stryker, NVIDIA, ResMed, and Ralph Lauren combining strong growth prospects with attractive valuations for maximum returns.
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
Wells Fargo Initiates Coverage on ResMed (RMD) with Equal-Weight Rating | RMD Stock News
Wells Fargo Initiates Coverage on ResMed (RMD) with Equal-Weight Rating | RMD Stock News
Zacks.com featured highlights include ResMed, Safran, Pentair, Casey's and Leonardo
Amid market uncertainty, low-leverage stocks RMD, SAFRY, PNR, CASY, and DRS emerge as safer investment options for steady growth.
5 Low-Leverage Stocks to Buy as Market Takes a Tumble
As markets tumble, low-leverage stocks like RMD, SAFRY, PNR, CASY, and DRS offer safer investment options for steady returns.
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, O...
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Competitive Strengths
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Competitive Strengths
Top 50 High-Quality Dividend Growth Stocks For October 2025
I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future ...
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks.com featured highlights include GE Aerospace, ResMed, Vertiv and National Fuel Gas
GE Aerospace, ResMed, Vertiv, and National Fuel Gas emerge as Zacks GARP picks, blending growth prospects with value appeal.
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, RMD, VRT and NFG are some such stocks.
ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript
ResMed (RMD) Receives 'Buy' Rating from Citigroup with $330 Price Target | RMD Stock News
ResMed (RMD) Receives 'Buy' Rating from Citigroup with $330 Price Target | RMD Stock News
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present...
The sleep economy is 'having a moment', says medical equipment firm Resmed
Carlos Nunez, Chief Medical Officer of Resmed takes about the opportunities and challenges in the sleep economy with CNBC's Martin Soong. He joins 'Squawk Box Asia' on the sidelines of the World Sleep...
The sleep economy is 'having a moment', says medical equipment firm Resmed
Carlos Nunez, Chief Medical Officer of Resmed takes about the opportunities and challenges in the sleep economy with CNBC's Martin Soong. He joins 'Squawk Box Asia' on the sidelines of the World Sleep...
Top 50 High-Quality Dividend Stocks For September 2025
I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto...
ResMed Inc (RMD) Launches Global Initiative to Revolutionize Sleep Health Care | RMD stock news
ResMed Inc (RMD) Launches Global Initiative to Revolutionize Sleep Health Care | RMD stock news
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care New global clinical insights initiative debuts at World Sleep Congress 2025 to...
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the public...
ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also ann...
How Resmed’s Mick Farrell turned a $7b company into a $62b giant
Family business successions are often a disaster. At ResMed, the global sleep device manufacturer, it has proven to be a winning formula.
Top 50 High-Quality Dividend Stocks For August 2025
My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated futur...